Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 31, 2012

View Archived Issues

Astrocyte-based therapy proven effective in Alzheimer's disease model

Daiichi Sankyo patents new tyrosine-protein kinase inhibitors

Janssen Pharmaceutica divulges new MMP inhibitors

Spanish researchers disclose new GSK-3 beta inhibitors

Soligenix regains North American and European rights to oral BDP

Data presented from a randomized trial comparing rehydration methods in children

BP-2-047 shows antitumor activity against STAT3-activated myeloma in vitro

Baxter presents clinical results for its rFIX protein as hemophilia B treatment

Targeted methods of protein gene therapy for the treatment of brain injury

Janus Biotherapeutics presents novel TLR9 antagonists

Xoma Corp. patents new monoclonal antibodies

Scientists at Lacer divulge novel agents for pain

Novel protein kinase inhibitors prepared at Bayer Intellectual Property

New conjugate presented for metabolic syndrome

Omeros reports results from pivotal phase III trial of OMS-103HP in surgical patients

Johns Hopkins receives additional NIH grant for studies of Q-Cells in ALS

Biotie's nepicastat fails to show efficacy in relieving PTSD symptoms

SBI Holdings reorganizes consolidated subsidiaries to improve efficiency

Japanese group enters agreement for new anticancer compounds

CytImmune and AstraZeneca to study new cancer nanomedicine

FDA accepts supplemental BLA filing for Xiaflex

Kissei submits application in Japan for combination therapy including Glufast

FDA approves Eliquis

Significant reduction in plasma antithrombin demonstrated in nonhuman primates

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...